United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TOKYO and CAMBRIDGE, England, Sept. 28, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration...

Sosei Heptares announces that a second novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials

Moderna

These players -- a biotech and a pharma giant -- are leading in terms of timeline, data, and the logistics of bringing a vaccine to the masses.

The 2 Coronavirus Vaccine Stocks I'd Buy Right Now

Abbott Labs

Teladoc

These stocks are perfectly positioned if the COVID-19 pandemic worsens in the U.S.

A Second Wave of Coronavirus Could Be Coming: 3 Stocks to Buy Before It Hits

Our indicative theme of Coronavirus Vaccine stocks - which includes a diverse set of U.S. based pharma and biotech stocks that are working on Covid-19 vaccines - is up by over 670% year-to-date, on an equally weighted basis, compared to the S&P 500 which has gained just about 3% over the same period

Moderna, Pfizer: Are Covid Vaccine Stocks A Buy As Markets Await Efficacy Data?

Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori,  for a hematologic indication gets priority review from the FDA.

Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328th consecutive quarterly dividend paid by Pfizer. Pfizer Inc.: Breakthroughs that change patients’ lives At Pfizer, we apply science and our global resources to bring therapies t

Pfizer Declares Fourth-Quarter 2020 Dividend

Don't just look at this company's experimental COVID-19 vaccine; there are other reasons to consider investing in it.

Here's My Top Coronavirus Vaccine Stock to Buy

AstraZeneca

Inovio Pharmaceuticals

Novavax

Today, investors are better prepared to choose potential winners.

Now Is the Perfect Time to Invest in Coronavirus Vaccine Stocks

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive. XALKORI received Breakthrough Therapy designation (BTD) for the ALK-positive ALCL indication in

FDA Accepts Supplemental New Drug Application for Pfizer’s XALKORI® (crizotinib) for the Treatment of Pediatric ALK-positive Anaplastic Large Cell Lymphoma

BioNTech SE

Regeneron Pharmaceuticals

These companies may be near-term and long-term winners -- thanks to coronavirus work and solid product portfolios.

3 Safe Coronavirus Stocks to Buy Ahead of a Market Crash

PARIS & NEW YORK--(BUSINESS WIRE)--Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inherited liver disorders with high unmet medical need, and Pfizer Inc. (NYSE: PFE) announced today that they have entered into a manufacturing agreement, under which Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson diseas

Vivet Therapeutics and Pfizer Inc. Enter into Manufacturing Agreement for Vivet’s Investigational Gene Therapy for Wilson Disease

PFE's dividend yield as well as prospects for a Covid-19 vaccine should put Pfizer stock on the radar of long-term investors.
The post Pfizer Shares May Catch Momentum Soon From Vaccine Work appeared first on InvestorPlace.

Pfizer Shares May Catch Momentum Soon From Vaccine Work

Expect Pfizer to skyrocket come October as it attempts to produce a vaccine for the novel coronavirus in record time. PFE stock is a buy.

Pfizer Is Your Best Bet at a Covid-19 Vaccine Play

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 27, 2020. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2020 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Info

Pfizer Invites Public to View and Listen to Webcast of October 27 Conference Call with Analysts

The big drugmaker could soon up its game in the lung cancer market.

Why Pfizer's Latest Big Win Makes It an Even Better Buy for Retirees

Optimism that vaccines are on the way to end the coronavirus pandemic has been a major factor in this year’s U.S. stock resurgence.

COVID-19 vaccine verdicts loom as next big market risk

BOULDER, Colo.--(BUSINESS WIRE)--OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib.

OnKure and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Combination of OKI-179 and Binimetinib

Apple

Axovant Gene Therapies Ltd

American Express

JPMorgan Chase & Co

Coca-Cola

McDonald's

Merck

NIKE

Sutro Biopharma Inc

Walmart

Sio Gene Therapies

Week 39 MDA Breakout Forecast: Short-Term Picks To Give You An Edge

Adverse event(s?) with AstraZeneca/Oxford University Phase 3 trial need more clarity for public confidence; the adverse event(s?) came after the second dose of the vaccine.

COVID-19 Vaccine Car Crash

Johnson & Johnson

You don't have to take on a huge amount of risk to profit from these solid COVID-19 vaccine leaders.

3 Best Coronavirus Vaccine Stocks to Buy Right Now

Amgen

Coronavirus concerns seem to be lifting as the markets churn higher, but is this a carrot-or-the-stick question?

This Week in Coronavirus News

Investors came back to the biotech's shares early this week. But will the optimism stick?

Are the Gains Over for This Early Leader in the Coronavirus Vaccine Race?

There's also one other candidate that's hot on their heels.

3 Coronavirus Vaccines in Phase 3 Clinical Studies: How They Stack Up Against Each Other

ROCKLAND, Mass. and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study...

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine

Mylan

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

News for Pfizer Stock (PFE)